Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors
April 26 2021 - 6:00AM
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage
biopharmaceutical company on a mission to develop treatments that
restore cognitive function, announced today the appointment of
Errol De Souza, Ph.D., to its board of directors.
Dr. De Souza is a seasoned R&D and business
leader with broad experience - from large pharma to start ups - in
the discovery and development of therapeutics for the treatment of
central nervous system (CNS) disorders. Dr. De Souza is currently
the executive chairman of Bionomics Limited and a member of the
board of directors of Royalty Pharma and Catalyst Biosciences.
Previously, Dr. De Souza founded Neurocrine Biosciences, Inc.,
served as CEO of numerous publicly traded and private companies,
including Biodel, Inc., Synaptic Pharmaceutical Corp., Archemix
Corp. and Neuropore Therapies, Inc. In addition, he led CNS R&D
at DuPont Merck and US R&D at Aventis. Dr. De Souza received a
B.A. in physiology and a Ph.D. in endocrinology from the University
of Toronto.
"We are excited to welcome Errol to the
Cyclerion Board of Directors. With deep expertise in CNS drug
development and strategic business experience at the highest levels
of biotech leadership, Errol will provide important counsel to help
shape the future of Cyclerion," said Peter Hecht, Ph.D. chief
executive officer of Cyclerion. “We seek board members with strong
strategic judgment, an owner-oriented mindset, business savvy, a
strong interest in our company, and absolute integrity, and Errol
embodies all of those attributes and will serve as an outstanding
representative of our shareholders and advisor to our company.”
"I have great respect for the Cyclerion team's
drug-making expertise and the potential for modulation of the
NO-sGC-cGMP pathway to positively impact brain physiology," said
Dr. De Souza. "I look forward to joining Cyclerion's
highly-committed board at this pivotal time to provide guidance on
the company's strategy and support the mission of creating
therapies that restore cognitive function for patients."
About Cyclerion
Therapeutics Cyclerion Therapeutics is a
clinical-stage biopharmaceutical company on a mission to develop
treatments that restore cognitive function. Cyclerion’s lead
molecule is CY6463, a novel, first-in-class, CNS-penetrant, sGC
stimulator that modulates a key node in a fundamental CNS signaling
network. The multidimensional pharmacology elicited by the
stimulation of sGC has the potential to impact a broad range of CNS
diseases. CY6463 has shown rapid improvement in biomarkers
associated with cognitive function and is currently in clinical
development for Alzheimer's Disease with Vascular pathology (ADv)
and Mitochondrial Encephalomyopathy, Lactic Acidosis and
Stroke-like episodes (MELAS).
For more information about Cyclerion, please
visit https://www.cyclerion.com/ and follow us on Twitter
(@Cyclerion) and LinkedIn (www.linkedin.com/company/cyclerion).
Forward Looking StatementThis press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Our
forward-looking statements are based on current beliefs and
expectations of our management team that involve risks, potential
changes in circumstances, assumptions, and uncertainties. We may,
in some cases use terms such as “predicts,” “believes,”
“potential,” “continue,” “anticipates,” “estimates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “likely,” “will,”
“should” or other words that convey uncertainty of the future
events or outcomes to identify these forward-looking statements.
Each forward-looking statement is subject to risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied in such statement. Applicable risks
and uncertainties include the risks listed under the heading “Risk
Factors” and elsewhere in our 2020 Form 10-K filed on February
25, 2021. Investors are cautioned not to place undue reliance on
these forward-looking statements. These forward-looking statements
(except as otherwise noted) speak only as of the date of this press
release, and Cyclerion undertakes no obligation to update these
forward-looking statements, except as required by law.
InvestorsCarlo Tanzi, Ph.D.Kendall Investor
Relationsctanzi@kendallir.com
MediaAmanda SellersVerge Scientific
Communicationsasellers@vergescientific.com
Cyclerion Therapeutics (NASDAQ:CYCN)
Historical Stock Chart
From Apr 2024 to May 2024
Cyclerion Therapeutics (NASDAQ:CYCN)
Historical Stock Chart
From May 2023 to May 2024